NCS Clinical Trials
At Northwest Cancer Specialists we sponsor more clinical trials than any other cancer treatment facility in the Portland-Vancouver area.
NCS won the prestigious American Cancer Society of Clinical Oncology (ASCO) Clinical Trial Participation Award in 2007.
Please see below for more information on our open trials.
Breast
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-Positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor (Study #06030)
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic (Study # 06185)
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (Study #07119)
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (Study #07132)
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer (PEG-SN38) (Study #07142)
Ixabepilone + Carboplatin Metastatic Breast Cancer (Study #08007)
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer (Study #08077)
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer (ExteNET) (Study #08201)
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1) (Study #08217)
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3) (Study #08223)
Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer (Study #09168)
GU Malignancies
Gemzar, Cisp, Sunitinib Urothelial Ca (Study #06040)
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (GIDEON) (Study #08142)
Intravenous BI 6727 in 2nd Line Treatment of Urothelial Cancer (Study #09049)
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail) (Study #09073)
GI Malignancies
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors (Study #08113)
Gynecologic Malignancies
Platinum Resistant Ovarian Cancer Evaluation of Doxil and EC14 Combination Therapy (Study #08099)
BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer (Study #08194)
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse (Study #09091)
Hematologic Malignancies
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) (Study #07152)
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (RACE) (Study #08061)
Ofatumumab + Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1) (Study #08074)
Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy. (PILLAR-1) (Study #08087)
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (PCYC-04753) (Study #09039)
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients (Study #09064)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study) (Study #09129)
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study (Study #09170)
Lung
RADIANT: A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in NSCLC Patients Who Have EGFR-Positive Tumors (Adjuvent) (Study #06026)
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer (Study #07155)
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy (Study #08035)
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer (Study #08044)
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer (Study #08094)
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer (Study #09015)
A Study of Advanced or Metastatic Non-small Cell Lung Cancer (Study #09078)
Melanoma
A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma (Study #09119)
Multiple Myelomas
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients (Study #08209)
Translational Oncology
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma (Study #05033)
Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification (Study #09062)
Study of XL184 in Adults With Advanced Malignancies (Study #09101)
|
